EVKEEZA (evinacumab) is used to treat adults and children aged 5 years and older with very high cholesterol caused by a condition called homozygous familial hypercholesterolemia (HoFH). EVKEEZA is used with a low-fat diet and other medicines to bring down cholesterol levels.
EVKEEZA at a glance:
- Is used to treat HoFH in adults and children 5 and older in combination with other lipid lowering therapies and low-fat diet
- Reduces the the level of LDL-cholesterol in the blood
- Is a 60-minute IV infusion, given every 4 weeks
What is HoFH?
- People with HoFH have extremely high levels of LDL-cholesterol—or ‘bad cholesterol’—from birth.
- Cholesterol levels this high can lead to heart problems at a early age.
- HoFH runs in families and it is usually passed down by both father and mother.
EVKEEZA works differently from other cholesterol-lowering treatments
HoFH is a serious disease that is inherited from one's parents that dramatically limits the body’s ability to remove bad cholesterol (LDL-C), which causes extremely high levels of bad cholesterol to remain in the body.
With HoFH, ANGPTL3 (a protein) stops the body from removing bad cholesterol. EVKEEZA was developed to block the effects of ANGPTL3.
Evinacumab, the active substance in Evkeeza, attaches to a protein in the body called ANGPTL3 and blocks its effects. ANGPTL3 is involved in controlling cholesterol levels. When evinacumab blocks the effects of ANGPLT3, the level of LDL-cholesterol in the blood is reduced and problems caused by high LDL-cholesterol levels may also be reduced.
Learn more about EVKEEZA